Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review

Journal of Advanced Research

Volumn 8, Issue 6, 2017, Pages 591-605

  Al Abd, Ahmed M ^a,b,c   Alamoudi, Abdulmohsin J ^b   Abdel Naim, Ashraf B ^b,d   Neamatallah, Thikryat A ^b   Ashour, Osama M ^b,e  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c Biomedical Research Section   (Egypt)

^d Ain Shams University   (Egypt)

^e Minia University   (Egypt)

Author keywords

Angiogenesis inhibitors; Natural products; Receptor protein tyrosine kinase; Tumor microenvironment

Indexed keywords

EID: 85026651730     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2017.06.006     Document Type: Review

References (201)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66:1 (2016), 7–30.
2. mortality data – CDC/NCHS, NVSS, mortality Revised. 2002 mortality Data-NVSR-Death final Data 2002-Volume 53, No. 5. Cost data from American Cancer Society Cancer & Figures 2005; 2002.
3. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J Clin 65:2 (2015), 87–108.
4. Al-Abd, A.M., Aljehani, Z.K., Gazzaz, R.W., Fakhri, S.H., Jabbad, A.H., Alahdal, A.M., et al. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release 219 (2015), 269–277.
5. Albini, A., Tosetti, F., Li, V.W., Noonan, D.M., Li, W.W., Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9:9 (2012), 498–509.
6. Zhao, Y., Adjei, A.A., Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20:6 (2015), 660–673.
7. Wang, Z., Dabrosin, C., Yin, X., Fuster, M.M., Arreola, A., Rathmell, W.K., et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 35:Suppl. (2015), S224–S243.
8. Khalid, E.B., Ayman, E.E., Rahman, H., Abdelkarim, G., Najda, A., Natural products against cancer angiogenesis. Tumour Biol 37:11 (2016), 14513–14536.
9. Lenzi, P., Bocci, G., Natale, G., John Hunter and the origin of the term “angiogenesis”. Angiogenesis 19:2 (2016), 255–256.
10. Folkman, J., Shing, Y., Control of angiogenesis by heparin and other sulfated polysaccharides. Heparin and related polysaccharides. Adv Exp Med Biol 313 (1992), 355–364.
11. Swift, M.R., Weinstein, B.M., Arterial–venous specification during development. Circ Res 104:5 (2009), 576–588.
12. Hanahan, D., Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:3 (1996), 353–364.
13. Folkman, J., Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:3 (1972), 409–416.
14. Maj, E., Papiernik, D., Wietrzyk, J., Antiangiogenic cancer treatment: the great discovery and greater complexity (Review). Int J Oncol 49:5 (2016), 1773–1784.
15. Baeriswyl V, Christofori G, editors. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009;19(5):329–37.
16. Payen, V.L., Brisson, L., Dewhirst, M.W., Sonveaux, P., Common responses of tumors and wounds to hypoxia. Cancer J 21:2 (2015), 75–87.
17. Hashimoto, T., Shibasaki, F., Hypoxia-inducible factor as an angiogenic master switch. Front Pediatr, 3, 2015, 33.
18. Ribatti, D., Nico, B., Crivellato, E., Roccaro, A., Vacca, A., The history of the angiogenic switch concept. Leukemia 21:1 (2007), 44–52.
19. Laurenzana, A., Fibbi, G., Margheri, F., Biagioni, A., Luciani, C., Del Rosso, M., et al. Endothelial progenitor cells in sprouting angiogenesis: proteases pave the way. Curr Mol Med 15:7 (2015), 606–620.
20. Kirsch, M., Schackert, G., Black, P.M., Angiogenesis, metastasis, and endogenous inhibition. J Neurooncol 50:1–2 (2000), 173–180.
21. Nicosia, R.F., Tchao, R., Leighton, J., Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metas 4:2 (1986), 91–104.
22. Bielenberg, D.R., Zetter, B.R., The contribution of angiogenesis to the process of metastasis. Cancer J 21:4 (2015), 267–273.
23. Raica, M., Cimpean, A.M., Ribatti, D., Angiogenesis in pre-malignant conditions. Eur J Cancer 45:11 (2009), 1924–1934.
24. Turner, H.E., Harris, A.L., Melmed, S., Wass, J.A., Angiogenesis in endocrine tumors. Endocr Rev 24:5 (2003), 600–632.
25. Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:5933 (2009), 1457–1461.
26. Kirsch, M., Schackert, G., Black, P.M., Metastasis and angiogenesis. Cancer Treat Res 117 (2004), 285–304.
27. Nagy JA, Chang S-H, Shih S-C, Dvorak AM, Dvorak HF, editors. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010;36(3):321–31.
28. Raza, A., Franklin, M.J., Dudek, A.Z., Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85:8 (2010), 593–598.
29. Kech, P., Hauser, S., Krivi, G., Sanzo, K., Warren, T., Feder, J., et al. Vascular permeability factor, an endothelial cell mitogen related to platelet derived growth factor. Science 246:4935 (1989), 1309–1312.
30. Tozer, G.M., Kanthou, C., Baguley, B.C., Disrupting tumour blood vessels. Nat Rev Cancer 5:6 (2005), 423–435.
31. Skliarenko, J.V., Lunt, S.J., Gordon, M.L., Vitkin, A., Milosevic, M., Hill, R.P., Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Can Res 66:4 (2006), 2074–2080.
32. Robinson, S.P., McIntyre, D.J., Checkley, D., Tessier, J.J., Howe, F.A., Griffiths, J.R., et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88:10 (2003), 1592–1597.
33. Seidi, K., Jahanban-Esfahlan, R., Zarghami, N., Tumor rim cells: from resistance to vascular targeting agents to complete tumor ablation. Tumour Biol, 39(3), 2017 1010428317691001.
34. Wong, P.P., Bodrug, N., Hodivala-Dilke, K.M., Exploring novel methods for modulating tumor blood vessels in cancer treatment. Curr Biol 26:21 (2016), R1161–R1166.
35. Bielenberg, D.R., Zetter, B.R., The contribution of angiogenesis to the process of metastasis. Cancer J 21:4 (2015), 267–273.
36. Paduch, R., The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol (Dordr) 39:5 (2016), 397–410.
37. S-h, Li., Tian, H., W-m, Yue., Li, L., W-j, Li., Z-t, Chen., et al. Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Ann Surg Oncol 18:7 (2011), 2048–2056.
38. Antiangiogenesis – list results – Clinicaltrials.Gov. Clinicaltrials.gov. N.p., 2017. Web. 23 Apr. 2017; 2017.
39. Ran, S., Volk, L., Hall, K., Flister, M.J., Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17:4 (2010), 229–251.
40. Medinger, M., Passweg, J., Role of tumour angiogenesis in haematological malignancies. Swiss Med Wkly, 144, 2014, w14050.
41. Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., Klagsbrun, M., Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223:4642 (1984), 1296–1299.
42. Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473:7347 (2011), 298–307.
43. Kim, K.J., Li, B., Houck, K., Winer, J., Ferrara, N., The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:1 (1992), 53–64.
44. Vasudev, N.S., Reynolds, A.R., Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:3 (2014), 471–494.
45. Dvorak, H.F., Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:21 (2002), 4368–4380.
46. Fischer, C., Mazzone, M., Jonckx, B., Carmeliet, P., FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 8:12 (2008), 942–956.
47. Tammela, T., Alitalo, K., Lymphangiogenesis: molecular mechanisms and future promise. Cell 140:4 (2010), 460–476.
48. Lee, S., Chen, T.T., Barber, C.L., Jordan, M.C., Murdock, J., Desai, S., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:4 (2007), 691–703.
49. Zhang J, Li Y, editors. Therapeutic uses of FGFs. Semin Cell Dev Biol 2016;53:144–54.
50. Khan, K.A., Bicknell, R., Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metas 33:2 (2016), 197–210.
51. Kopetz, S., Hoff, P.M., Morris, J.S., Wolff, R.A., Eng, C., Glover, K.Y., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:3 (2010), 453–459.
52. Khalid, E.B., Ayman, E.E., Rahman, H., Abdelkarim, G., Najda, A., Natural products against cancer angiogenesis. Tumor Biol 37:11 (2016), 14513–14536.
53. Compagni, A., Wilgenbus, P., Impagnatiello, M.-A., Cotten, M., Christofori, G., Fibroblast growth factors are required for efficient tumor angiogenesis. Can Res 60:24 (2000), 7163–7169.
54. Wang, L., Park, H., Chhim, S., Ding, Y., Jiang, W., Queen, C., et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther 11:4 (2012), 864–872.
55. Heldin, C.-H., Eriksson, U., Östman, A., New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398:2 (2002), 284–290.
56. Zhao, Y., Adjei, A.A., Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20:6 (2015), 660–673.
57. Dewerchin, M., Carmeliet, P., PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med, 2, 2012, a011056.
58. Nielsen, D.L., Sengeløv, L., Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Expert Opin Biol Ther 12:6 (2012), 795–804.
59. Thomas, M., Augustin, H.G., The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12:2 (2009), 125–137.
60. Yuan, H.T., Khankin, E.V., Karumanchi, S.A., Parikh, S.M., Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 29:8 (2009), 2011–2022.
61. Graveel, C.R., Tolbert, D., Woude, G.F.V., MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol, 5(7), 2013, a009209.
62. Jahangiri, A., De Lay, M., Miller, L.M., Carbonell, W.S., Hu, Y.-L., Lu, K., et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:7 (2013), 1773–1783.
63. Verrienti, A., Tallini, G., Colato, C., Boichard, A., Checquolo, S., Pecce, V., et al. RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocr Relat Cancer 23:8 (2016), 665–676.
64. Elisei, R., Schlumberger, M.J., Müller, S.P., Schöffski, P., Brose, M.S., Shah, M.H., et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:29 (2013), 3639–3646.
65. Kuhnert, F., Kirshner, J.R., Thurston, G., Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell, 3(1), 2011, 1.
66. Hellström, M., Phng, L.-K., Hofmann, J.J., Wallgard, E., Coultas, L., Lindblom, P., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445:7129 (2007), 776–780.
67. Patel, N.S., Li, J.-L., Generali, D., Poulsom, R., Cranston, D.W., Harris, A.L., Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Can Res 65:19 (2005), 8690–8697.
68. Limbourg, F.P., Takeshita, K., Radtke, F., Bronson, R.T., Chin, M.T., Liao, J.K., Essential role of endothelial Notch1 in angiogenesis. Circulation 111:14 (2005), 1826–1832.
69. Yan, M., Callahan, C.A., Beyer, J.C., Allamneni, K.P., Zhang, G., Ridgway, J.B., et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463:7282 (2010), E6–E7.
70. Mosch B, Reissenweber B, Neuber C, Pietzsch J. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol 2010;2010.
71. Cheng, N., Brantley, D.M., Liu, H., Lin, Q., Enriquez, M., Gale, N., et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1:1 (2002), 2–11.
72. Sawamiphak, S., Seidel, S., Essmann, C.L., Wilkinson, G.A., Pitulescu, M.E., Acker, T., et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465:7297 (2010), 487–491.
73. Weis S, Cheresh D. alphaV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 2011;1:a006478.
74. Friedlander, M., Brooks, P.C., Shaffer, R.W., Kincaid, C.M., Definition of two angiogenic pathways by distinct alphav integrins. Science 270:5241 (1995), 1500–1502.
75. Wang, Z., Yan, X., CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:2 (2013), 150–162.
76. Zeng, Q., Wu, Z., Duan, H., Jiang, X., Tu, T., Lu, D., et al. Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell 5:6 (2014), 445–456.
77. Flanagan, K., Fitzgerald, K., Baker, J., Regnstrom, K., Gardai, S., Bard, F., et al. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS ONE, 7(7), 2012, e40443.
78. Tu, T., Zhang, C., Yan, H., Luo, Y., Kong, R., Wen, P., et al. CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res 25:3 (2015), 275–287.
79. Dejana, E., Giampietro, C., Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 19:3 (2012), 218–223.
80. Prandini, M.-H., Dreher, I., Bouillot, S., Benkerri, S., Moll, T., Huber, P., The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene 24:18 (2005), 2992–3001.
81. Li, H., Shi, X., Liu, J., Hu, C., Zhang, X., Liu, H., et al. The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation. Cancer Gene Ther 17:10 (2010), 700–707.
82. Chaudhary, A., Hilton, M.B., Seaman, S., Haines, D.C., Stevenson, S., Lemotte, P.K., et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21:2 (2012), 212–226.
83. Ucuzian, A.A., Gassman, A.A., East, A.T., Greisler, H.P., Molecular mediators of angiogenesis. J Burn Care Res 31:1 (2010), 158–175.
84. Nolan-Stevaux, O., Zhong, W., Culp, S., Shaffer, K., Hoover, J., Wickramasinghe, D., et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS ONE, 7(12), 2012, e50920.
85. Umikawa, M., Umikawa, A., Asato, T., Takei, K., Matsuzaki, G., K-i, Kariya., et al. Angiopoietin-like protein 2 induces proinflammatory responses in peritoneal cells. Biochem Biophys Res Commun 467:2 (2015), 235–241.
86. Gaur, P., Bielenberg, D.R., Samuel, S., Bose, D., Zhou, Y., Gray, M.J., et al. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res 15:22 (2009), 6763–6770.
87. Neufeld, G., Sabag, A.D., Rabinovicz, N., Kessler, O., Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med, 2(1), 2012, a006718.
88. Zhou, H., Binmadi, N.O., Yang, Y.-H., Proia, P., Basile, J.R., Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 15:3 (2012), 391–407.
89. Leszczynska, K., Kaur, S., Wilson, E., Bicknell, R., Heath, V.L., The role of RhoJ in endothelial cell biology and angiogenesis. Biochem Soc Trans 39:6 (2011 Dec), 1606–1611.
90. Mura, M., Swain, R., Zhuang, X., Vorschmitt, H., Reynolds, G., Durant, S., et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 31:3 (2012), 293–305.
91. Noy, P., Lodhia, P., Khan, K., Zhuang, X., Ward, D., Verissimo, A., et al. Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene, 2015.
92. Berretta, M., Rinaldi, L., Di Benedetto, F., Lleshi, A., De Re, V., Facchini, G., et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol, 7, 2016, 428.
93. Raddum, A.M., Evensen, L., Hollås, H., Grindheim, A.K., Lorens, J.B., Vedeler, A., Domains I and IV of annexin A2 affect the formation and integrity of in vitro capillary-like networks. PLoS ONE, 8(3), 2013, e60281.
94. Raddum, A.M., Hollås, H., Shumilin, I.A., Henklein, P., Kretsinger, R., Fossen, T., et al. The native structure of annexin A2 peptides in hydrophilic environment determines their anti-angiogenic effects. Biochem Pharmacol 95:1 (2015), 1–15.
95. Shimizu, T., Kurozumi, K., Ishida, J., Ichikawa, T., Date, I., Adhesion molecules and the extracellular matrix as drug targets for glioma. Brain Tumor Pathol 33:2 (2016), 97–106.
96. Lombardi, G., Pambuku, A., Bellu, L., Farina, M., Della Puppa, A., Denaro, L., et al. Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 111 (2017), 94–102.
97. Tewari, K.S., Sill, M.W., Long, H.J. III, Penson, R.T., Huang, H., Ramondetta, L.M., et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:8 (2014), 734–743.
98. Lin, Z., Zhang, Q., Luo, W., Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions. Eur J Pharmacol, 2016.
99. Grabowski, J., Glode, A., Ramucirumab: a vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies. Am J Health Syst Pharm 73:13 (2016), 957–968.
100. Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19:24 (2013), 6730–6740.
101. Ricci, V., Ronzoni, M., Fabozzi, T., Aflibercept a new target therapy in cancer treatment: a review. Crit Rev Oncol Hematol 96:3 (2015), 569–576.
102. Scartozzi, M., Vincent, L., Chiron, M., Cascinu, S., Aflibercept, a new way to target angiogenesis in the second line treatment of metastatic colorectal cancer (mCRC). Target Oncol 11:4 (2016), 489–500.
103. Liontos, M., Lykka, M., Bamias, A., Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. Onco Targets Ther 7 (2014), 1837–1845.
104. Abou-Alfa GK, Blanc J-F, Miles S, Ganten TM, Trojan J, Cebon JS, et al., editors. Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC). In: ASCO annual meeting proceedings; 2014.
105. Al Wadi, K., Ghatage, P., Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer. Expert Opin Pharmacother 17:6 (2016), 853–860.
106. Li, D., Wei, X., Xie, K., Chen, K., Li, J., Fang, J., A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer 111:1 (2014), 68–77.
107. Noguera-Troise, I., Daly, C., Papadopoulos, N.J., Coetzee, S., Boland, P., Gale, N.W., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:7122 (2006), 1032–1037.
108. Brantley, D.M., Cheng, N., Thompson, E.J., Lin, Q., Brekken, R.A., Thorpe, P.E., et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21:46 (2002), 7011–7026.
109. Strawn, L.M., McMahon, G., App, H., Schreck, R., Kuchler, W.R., Longhi, M.P., et al. Flk-1 as a target for tumor growth inhibition. Can Res 56:15 (1996), 3540–3545.
110. Baumann, K., Du Bois, A., Meier, W., Rau, J., Wimberger, P., Sehouli, J., et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 23:9 (2012), 2265–2271.
111. Iyer, R., Fetterly, G., Lugade, A., Thanavala, Y., Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11:11 (2010), 1943–1955.
112. Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, et al. Benefit, risk, and outcomes in drug development: a systematic review of sunitinib. J Natl Cancer Inst 2016;108(1):djv292.
113. Johnson, P.J., Qin, S., Park, J.-W., Poon, R.T., Raoul, J.-L., Philip, P.A., et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:28 (2013), 3517–3524.
114. Wedge, S.R., Kendrew, J., Hennequin, L.F., Valentine, P.J., Barry, S.T., Brave, S.R., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Can Res 65:10 (2005), 4389–4400.
115. Angevin, E., Lopez-Martin, J.A., Lin, C.-C., Gschwend, J.E., Harzstark, A., Castellano, D., et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:5 (2013), 1257–1268.
116. Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., Asada, M., Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:17 (2008), 5459–5465.
117. Cainap, C., Qin, S., Huang, W.-T., Chung, I.J., Pan, H., Cheng, Y., et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:2 (2015), 172–179.
118. Zhou, J., Goh, B.C., Albert, D.H., Chen, C.S., ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol, 2, 2009, 33.
119. Kumar, V., Chhibber, S., Thalidomide: an old drug with new action. J Chemother 23:6 (2011), 326–334.
120. Sherbet, G.V., Therapeutic potential of thalidomide and its analogues in the treatment of cancer. Anticancer Res 35:11 (2015), 5767–5772.
121. Kumar, S.K., Vij, R., Noga, S.J., Berg, D., Brent, L., Dollar, L., et al. Treating multiple myeloma patients with oral therapies. Clin Lymphoma Myeloma Leuk 17:5 (2017), 243–251.
122. Cragg, G.M., Newman, D.J., Plants as a source of anti-cancer agents. J Ethnopharmacol 100:1–2 (2005), 72–79.
123. Anderson, H.L., Yap, J.T., Miller, M.P., Robbins, A., Jones, T., Price, P.M., Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:15 (2003), 2823–2830.
124. Jaroch, K., Karolak, M., Gorski, P., Jaroch, A., Krajewski, A., Ilnicka, A., et al. Combretastatins: in vitro structure-activity relationship, mode of action and current clinical status. Pharmacol Rep 68:6 (2016), 1266–1275.
125. Zweifel, M., Jayson, G.C., Reed, N., Osborne, R., Hassan, B., Ledermann, J., et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:9 (2011), 2036–2041.
126. Ibrahim, M.A., Do, D.V., Sepah, Y.J., Shah, S.M., Van Anden, E., Hafiz, G., et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate. BMC Pharmacol Toxicol, 14, 2013, 7.
127. Liu, P., Qin, Y., Wu, L., Yang, S., Li, N., Wang, H., et al. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections. Anticancer Drugs 25:4 (2014), 462–471.
128. Na, Y., Recent cancer drug development with xanthone structures. J Pharm Pharmacol 61:6 (2009), 707–712.
129. LoRusso, P.M., Boerner, S.A., Hunsberger, S., Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?. J Clin Oncol 29:22 (2011), 2952–2955.
130. Kruczynski, A., Poli, M., Dossi, R., Chazottes, E., Berrichon, G., Ricome, C., et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42:16 (2006), 2821–2832.
131. Banerjee S, Hwang DJ, Li W, Miller DD. Current advances of tubulin inhibitors in nanoparticle drug delivery and vascular disruption/angiogenesis. Molecules 2016;21(11).
132. Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., McPhail, A.T., Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:9 (1971), 2325–2327.
133. Slaughter, K.N., Moore, K.N., Mannel, R.S., Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials. Curr Oncol Rep, 16(11), 2014, 412.
134. Kumar, M., Dhatwalia, S.K., Dhawan, D.K., Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis. Tumour Biol 37:11 (2016), 14341–14354.
135. Kunnumakkara, A.B., Anand, P., Aggarwal, B.B., Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:2 (2008), 199–225.
136. Abdel-Latif, G.A., Al-Abd, A.M., Tadros, M.G., Al-Abbasi, F.A., Khalifa, A.E., Abdel-Naim, A.B., The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Sci Rep, 5, 2015, 12054.
137. Khaleel, S.A., Al-Abd, A.M., Ali, A.A., Abdel-Naim, A.B., Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity. Sci Rep, 6, 2016, 36855.
138. López-Jiménez, A., García-Caballero, M., Medina, M.Á., Quesada, A.R., Anti-angiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary. Eur J Nutr 52:1 (2013), 85–95.
139. Igura, K., Ohta, T., Kuroda, Y., Kaji, K., Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171:1 (2001), 11–16.
140. Pratheeshkumar, P., Budhraja, A., Son, Y.-O., Wang, X., Zhang, Z., Ding, S., et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE, 7(10), 2012, e47516.
141. Su, S.J., Yeh, T.M., Chuang, W.J., Ho, C.L., Chang, K.L., Cheng, H.L., et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 69:2 (2005), 307–318.
142. Hosseini, A., Ghorbani, A., Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed 5:2 (2015), 84–97.
143. Garcia-Vilas, J.A., Martinez-Poveda, B., Quesada, A.R., Medina, M.A., Aeroplysinin-1, a sponge-derived multi-targeted bioactive marine drug. Mar Drugs, 14(1), 2015, 1.
144. Wahl, O., Oswald, M., Tretzel, L., Herres, E., Arend, J., Efferth, T., Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 18:21 (2011), 3136–3155.
145. Niemann, H., Marmann, A., Lin, W., Proksch, P., Sponge derived bromotyrosines: structural diversity through natural combinatorial chemistry. Nat Prod Commun 10:1 (2015), 219–231.
146. Wagner, S.C., Ichim, T.E., Ma, H., Szymanski, J., Perez, J.A., Lopez, J., et al. Cancer anti-angiogenesis vaccines: is the tumor vasculature antigenically unique?. J Transl Med, 13, 2015, 340.
147. Bussolati, B., Deambrosis, I., Russo, S., Deregibus, M.C., Camussi, G., Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 17:9 (2003), 1159–1161.
148. Grange, C., Bussolati, B., Bruno, S., Fonsato, V., Sapino, A., Camussi, G., Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 15:2 (2006), 381–386.
149. Xiong, Y.Q., Sun, H.C., Zhang, W., Zhu, X.D., Zhuang, P.Y., Zhang, J.B., et al. Human hepatocellular carcinoma tumor–derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15:15 (2009), 4838–4846.
150. Li, Y., Bohlen, P., Hicklin, D.J., Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy. Curr Mol Med 3:8 (2003), 773–779.
151. Gavilondo, J., Hernández-Bernal, F., Ayala-Ávila, M., de la Torre, A., de la Torre, J., Morera-Díaz, Y., et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 32:19 (2014), 2241–2250.
152. Chen, R., Wang, S., Yao, Y., Zhou, Y., Zhang, C., Fang, J., et al. Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide. Oncol Rep 33:5 (2015), 2269–2276.
153. Liang, P.H., Zhang, K.Q., Xu, G.L., Li, Y.F., Wang, L.F., Nie, Z.L., et al. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth. Cancer Immunol Immunother 59:1 (2010), 93–101.
154. Miyazawa, M., Ohsawa, R., Tsunoda, T., Hirono, S., Kawai, M., Tani, M., et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101:2 (2010), 433–439.
155. Fu, C., Bardhan, S., Cetateanu, N.D., Wamil, B.D., Wang, Y., Yan, H.-P., et al. Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. Clin Cancer Res 7:12 (2001), 4182–4194.
156. García, B., Neninger, E., de la Torre, A., Leonard, I., Martínez, R., Viada, C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:3 (2008), 840–846.
157. Lorente, A.F., Brooks, S.A., Vinageras, E.N., Alvarez, Md.C.B., Brito, B.W., Concepción, M.T., et al. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF. World J Surg Oncol, 11, 2013, 275.
158. Nerini, I.F., Cesca, M., Bizzaro, F., Giavazzi, R., Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer, 35(1), 2016, 61.
159. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:5706 (2005), 58–62.
160. Siemann, D.W., Rojiani, A.M., Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53:1 (2002), 164–171.
161. Liang, W., Ni, Y., Chen, F., Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions. Oncotarget 7:13 (2016), 15444–15459.
162. Horsman, M.R., Siemann, D.W., Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Can Res 66:24 (2006), 11520–11539.
163. Nagaiah, G., Remick, S.C., Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol 6:8 (2010), 1219–1228.
164. Kłosowska-Wardęga, A., Hasumi, Y., Burmakin, M., Åhgren, A., Stuhr, L., Moen, I., et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS ONE, 4(12), 2009, e8149.
165. Al-Abd, A.M., Al-Abbasi, F.A., Torchilin, V.P., Intratumoral pharmacokinetics: challenges to nanobiomaterials. Curr Pharm Des 21:22 (2015), 3208–3214.
166. Martinelli, M., Bonezzi, K., Riccardi, E., Kuhn, E., Frapolli, R., Zucchetti, M., et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97:7 (2007), 888–894.
167. Dickson, P.V., Hamner, J.B., Sims, T.L., Fraga, C.H., Ng, C.Y., Rajasekeran, S., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13:13 (2007), 3942–3950.
168. Zhou, F., Hu, J., Shao, J.-H., Zou, S.-B., Shen, S.-L., Luo, Z.-Q., Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 138:11 (2012), 1879–1890.
169. Carbone, C., Tamburrino, A., Piro, G., Boschi, F., Cataldo, I., Zanotto, M., et al. Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment. Anticancer Drugs 27:1 (2016), 29–40.
170. Ma, J., Waxman, D.J., Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7:12 (2008), 3670–3684.
171. Hsu, H.-W., Wall, N.R., Hsueh, C.-T., Kim, S., Ferris, R.L., Chen, C.-S., et al. Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol 50:1 (2014), 19–26.
172. Kamrava, M., Bernstein, M.B., Camphausen, K., Hodge, J.W., Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the three musketeers or just another quixotic combination?. Mol BioSyst 5:11 (2009), 1262–1270.
173. Kerbel, R.S., A cancer therapy resistant to resistance. Nature 390:6658 (1997), 335–336.
174. Kerbel, R.S., Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13:1 (1991), 31–36.
175. Kindler, H.L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:22 (2010), 3617–3622.
176. Saltz, L.B., Lenz, H.-J., Kindler, H.L., Hochster, H.S., Wadler, S., Hoff, P.M., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:29 (2007), 4557–4561.
177. Shojaei, F., Wu, X., Malik, A.K., Zhong, C., Baldwin, M.E., Schanz, S., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. Nat Biotechnol 25:8 (2007), 911–920.
178. Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:8 (2008), 592–603.
179. Fernando, N.T., Koch, M., Rothrock, C., Gollogly, L.K., D'Amore, P.A., Ryeom, S., et al. Tumor escape from endogenous, extracellular matrix–associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14:5 (2008), 1529–1539.
180. Mizukami, Y., Jo, W.-S., Duerr, E.-M., Gala, M., Li, J., Zhang, X., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells. Nat Med 11:9 (2005), 992–997.
181. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.-T., Duda, D.G., Cohen, K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:1 (2007), 83–95.
182. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:5302 (1997), 964–966.
183. Song, S., Ewald, A.J., Stallcup, W., Werb, Z., Bergers, G., PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7:9 (2005), 870–879.
184. Yang, L., DeBusk, L.M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., et al. Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:4 (2004), 409–421.
185. Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C.R., Man, S., Cheung, A.M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:5794 (2006), 1785–1787.
186. Mancuso, M.R., Davis, R., Norberg, S.M., O'Brien, S., Sennino, B., Nakahara, T., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:10 (2006), 2610–2621.
187. Bussard, K.M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., Marini, F.C., Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res: BCR, 18(1), 2016, 84.
188. Benjamin, L.E., Hemo, I., Keshet, E., A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:9 (1998), 1591–1598.
189. Darland, D., Massingham, L., Smith, S., Piek, E., Saint-Geniez, M., D'amore, P., Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264:1 (2003), 275–288.
190. Narayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival: clinical article. J Neurosurg 110:1 (2009), 173–180.
191. Norden, A., Young, G., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G., et al. Bevacizumab for recurrent malignant gliomas Efficacy, toxicity, and patterns of recurrence. Neurology 70:10 (2008), 779–787.
192. Jimenez-Valerio, G., Martinez-Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suarez, C., et al. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep 15:6 (2016), 1134–1143.
193. Sofuni, A., Iijima, H., Moriyasu, F., Nakayama, D., Shimizu, M., Nakamura, K., et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 40:5 (2005), 518–525.
194. Kaur, B., Tan, C., Brat, D.J., Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:2 (2004), 229–243.
195. Marty, M., Pivot, X., The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 44:7 (2008), 912–920.
196. Griffioen, A.W., Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?. Trends Cardiovasc Med 17:5 (2007), 171–176.
197. Miller, K.D., Sweeney, C.J., Sledge, G.W. Jr, Can tumor angiogenesis be inhibited without resistance?. EXS 94 (2005), 95–112.
198. Folkman, J., Fighting cancer by attacking its blood supply. Sci Am 275:3 (1996), 150–154.
199. Kuusk, T., Albiges, L., Escudier, B., Grivas, N., Haanen, J., Powles, T., et al. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis 20:2 (2017), 205–215.
200. Eisermann, K., Fraizer, G., The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers (Basel), 9(4), 2017.
201. Cao, Y., Future options of anti-angiogenic cancer therapy. Chin J Cancer, 35, 2016, 21.